The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Open accessAbstract
Alzheimer's disease and Parkinson's disease are associated with the cerebral accumulation of β-amyloid and α-synuclein, respectively. Some patients have clinical and pathological features of both diseases, raising the possibility of overlapping pathogenetic pathways. We generated transgenic (tg) mice with neuronal expression of human β-amyloid peptides, α-synuclein, or both. The functional and morphological alterations in doubly tg mice resembled the Lewy-body variant of Alzheimer's disease. These mice had severe deficits in learning and memory, developed motor deficits before α-synuclein singly tg mice, and showed prominent age-dependent degeneration of cholinergic neurons and presynaptic terminals. They also had more α-synuclein-immunoreactive neuronal inclusions than α-synuclein singly tg mice. Ultrastructurally, some of these inclusions were fibrillar in doubly tg mice, whereas all inclusions were amorphous in α-synuclein singly tg mice. β-Amyloid peptides promoted aggregation of α-synuclein in a cell-free system and intraneuronal accumulation of α-synuclein in cell culture. β-Amyloid peptides may contribute to the development of Lewy-body diseases by promoting the aggregation of α-synuclein and exacerbating α-synuclein-dependent neuronal pathologies. Therefore, treatments that block the production or accumulation of β-amyloid peptides could benefit a broader spectrum of disorders than previously anticipated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“The hαSyn/hAPP model recapitulated many of the clinical symptoms and pathology of AD-LBV.”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Further evidence of a link between αSyn and Aβ pathology was offered from studies using mice expressing wt human αSyn (hαSyn) and human APP (hAPP) (hαSyn/hAPP).”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationA Drosophila model of Parkinson's disease
Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,157
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,073
Research works printed but not linked: 3
- R D Terry, R Katzman, K L Bick, S S Sisodia Alzheimer Disease (Lippincott, Philadelphia, 1999).
- A Takeda, M Mallory, M Sundsmo, W Honer, L Hansen, E Masliah Am J Pathol 152, 367–372 (1998).
- D Van Gool, B De Strooper, F Van Leuven, R Dom Dementia 6, 63–68 (1995).
Cited by
Sorted by citations
Items 401–500 of 607
Synuclein aggregation: possible role in traumatic brain injury
Bramlett, H. M., & Dietrich, W. D. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00401-1 · Cited by 17
Alvarado, J. C., Fuentes‐Santamaría, V., Franklin, S. R., Brunso‐Bechtold, J. K., & Henkel, C. K. (2007) · Synapse · doi:10.1002/syn.20373 · Cited by 16
Beyer, K., Lao, J. I., Carrato, C., Mate, J. L., López, D., Ferrer, I., & Ariza, A. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.08.006 · Cited by 16
Liu, Y., Koyutürk, M., Maxwell, S., Zhao, Z., & Chance, M. R. (2012) · Europe PMC (PubMed Central) · Cited by 16
Windisch, M., Wolf, H.-J., Hutter‐Paier, B., & Wronski, R. (2008) · Neurodegenerative Diseases · doi:10.1159/000113707 · Cited by 16
Burn, D. J. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.025569 · Cited by 16
Lau, V. Z., Awogbindin, I. O., Frenkel, D., Whitehead, S. N., & Tremblay, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70363 · Cited by 16
Neubauer, A., Weissenbrunner, D., Pekrun, S., Roeber, S., Ruf, V. C., Feyen, P. L. C., Strübing, F., & Herms, J. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02952-w · Cited by 17
Jellinger, K. A. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02660-3 · Cited by 17
Li, Y., Ren, H., Chi, C., & Miao, Y. (2024) · Advanced Science · doi:10.1002/advs.202307819 · Cited by 15
Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 18
Maarouf, C. L., Beach, T. G., Adler, C. H., Malek‐Ahmadi, M. H., Kokjohn, T. A., Dugger, B. N., Walker, D. G., Shill, H. A., Jacobson, S. A., Sabbagh, M. N., et al. (2013) · Biomarker Insights · doi:10.4137/bmi.s11422 · Cited by 15
Yamashita, K., Hiwatashi, A., Togao, O., Kikuchi, K., Yamaguchi, H., Suzuki, Y., Kamei, R., Yamasaki, R., Kira, J., & Honda, H. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25489 · Cited by 15
Takamatsu, Y., Fujita, M., Ho, G. J., Wada, R., Sugama, S., Takenouchi, T., Waragai, M., Masliah, E., & Hashimoto, M. (2018) · Parkinson s Disease · doi:10.1155/2018/5789424 · Cited by 15
Self-citationVictorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 15
Dementia in Parkinson's Disease
Burn, D. J. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00012-x · Cited by 17
Lv, Y., Ding, X.-S., Gao, L., Han, Z., Feng, C., Li, Y.-N., Wang, Y., Yang, Q., Simon, D. K., Wang, X., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102995 · Cited by 17
Role of TREM2 in the Development of Neurodegenerative Diseases After Traumatic Brain Injury
Zhang, C., & Chen, S. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03094-w · Cited by 14
Новиков, Н. Ю., Brazhnik, E. S., & Kitchigina, V. F. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923110172 · Cited by 14
Na, S., Jeong, H. S., Park, J., Chung, Y., & Song, I. (2020) · Metabolites · doi:10.3390/metabo10100380 · Cited by 14
Selective Vulnerability of Neurons in Primary Cultures and in Neurodegenerative Diseases
Chen, J., & Herrup, K. (2008) · Reviews in the Neurosciences · doi:10.1515/revneuro.2008.19.4-5.317 · Cited by 15
Research models to study lewy body dementia
Boschen, S. L., Mukerjee, A. A., Faroqi, A. H., Rabichow, B. E., & Fryer, J. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00837-w · Cited by 16
The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients
Kim, K. J., Bae, Y. J., Kim, J., Kim, B. J., Oh, E., Yun, J. Y., Kim, J. S., & Kim, H. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e289 · Cited by 14
Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease
Murakami, H., Tokuda, T., El‐Agnaf, O. M. A., Ohmichi, T., Miki, A., Ohashi, H., Owan, Y., Saito, Y., Yano, S., Tsukie, T., et al. (2019) · BMC Neurology · doi:10.1186/s12883-019-1346-y · Cited by 13
Lee, J. E., Cho, K. H., Kim, M., Sohn, Y. H., & Lee, P. H. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6203-x · Cited by 13
Progress towards achieving new vaccine and vaccination goals
Ada, G. (2003) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2003.00365.x · Cited by 13
Lewthwaite, A. J., & Nicholl, D. J. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0064-6 · Cited by 12
Oligomerization by co-assembly of β-amyloid and α-synuclein
Kim, J. R. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1153839 · Cited by 13
Multiple system atrophy with amyloid-β-predominant Alzheimer’s disease neuropathologic change
Kon, T., Ichimata, S., Luca, D. G. D., Martínez-Valbuena, I., Kim, A., Yoshida, K., Alruwaita, A. A., Kleiner, G., Strafella, A. P., Forrest, S. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae141 · Cited by 13
Initiative, A. D. N., Li, J., Bi, Y., Shen, X., Wang, H.-F., Xu, W., Tan, C., Dong, Q., Wang, Y., Tan, L., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00222-1 · Cited by 12
Chang, C., Li, H., Chang, Y., Ho, Y., Hsieh, L., Chiu, P., Cheng, Y., Lin, C., & Lai, T. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12772 · Cited by 12
Relationship Between Tau, β Amyloid and α-Synuclein Pathologies
Walker, L., & Attems, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_14 · Cited by 12
Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders
Shan, F. Y., Fung, K., Zieneldien, T., Kim, J., Cao, C., & Huang, J. H. (2021) · Life · doi:10.3390/life11111126 · Cited by 13
A Novel NOX Inhibitor Treatment Attenuates Parkinson’s Disease-Related Pathology in Mouse Models
Ghosh, A., Verma, D., Cabrera, G., Ofori, K., Hernandez-Quijada, K., Kim, J., Chung, J. H., Moore, M., Moon, S. H., Seo, J. B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084262 · Cited by 12
Parkinson’s disease dementia: what’s in a Lewy body?
Burn, D. J. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_55 · Cited by 12
Following the leader: fibrillization of ?-synuclein and tau
Frasier, M. A. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.02.008 · Cited by 12
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
Santiago, J. A., & Potashkin, J. A. (2014) · Diagnostics · doi:10.3390/diagnostics4040153 · Cited by 11
A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid
Initiative, A. D. N., Zhong, X.-L., Li, J., Sun, L. J., Li, Y., Wang, H.-F., Cao, X., Tan, C., Wang, L., Tan, L., et al. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9922-2 · Cited by 11
Dong, C., Garen, C., Mercier, P., Petersen, N., & Woodside, M. (2019) · Protein Science · doi:10.1002/pro.3684 · Cited by 10
Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease
Hashimoto, M., Ho, G. J., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., Waragai, M., & Masliah, E. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191675 · Cited by 12
Self-citationGene-environment interplay in neurogenesis and neurodegeneration
Palomo, T., Archer, T., Beninger, R. J., & Kostrzewa, R. M. (2004) · Neurotoxicity Research · doi:10.1007/bf03033279 · Cited by 11
Impact of α-Synuclein Pathology on Aging
Parkkinen, L. (2005) · Cited by 11
Co‐pathologies modify hippocampal protein accumulation patterns in neurodegenerative diseases
Yoshida, K., Forrest, S. L., Ichimata, S., Tanaka, H., Kon, T., & Kovács, G. G. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14355 · Cited by 9
Voicu, V. A., Tătaru, C. P., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Corlatescu, A.-D., & Ciurea, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613006 · Cited by 12
UBL3 Interaction with α-Synuclein Is Downregulated by Silencing MGST3
Yan, J., Zhang, H., Chen, B., Ping, Y., Islam, M. S., Tomochika, Y., Aramaki, S., Sato, T., Nagashima, Y., Nakamura, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092491 · Cited by 11
Chapter V Motor function(s) of the nigrostriatal dopamine system: Studies of lesions and behavior
Dunnett, S. B. (2005) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(05)80009-0 · Cited by 10
Lipid Peroxidation in Chronic Cerebral HypoperfusionInduced Neurodegeneration in Rats
Anil Kumar, S., Saif, S. A., Oothuman, P., & Mia, M. (2011) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v10i2.560 · Cited by 10
Pharmacological approaches to disease-modifying therapies in Parkinson’s disease
O’Neill, M. J., & Siemers, E. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.6.819 · Cited by 10
Dewji, N. N., Singer, S. J., Masliah, E., Rockenstein, E. M., Kim, M., Harber, M., & Horwood, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122451 · Cited by 10
Self-citationLiang, J., Li, R., Wong, G., & Huang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00879-0 · Cited by 13
Thakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 10
Lv, S., Zhou, X., Li, Y., Zhang, S., Wang, Y., Jia, S., Niu, X., Wang, L., & Peng, D. (2021) · Medical Science Monitor · doi:10.12659/msm.932998 · Cited by 9
Gene Therapy for Alzheimer and Parkinson Diseases
Saad, J. F., & Saad, F. A. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230419101023 · Cited by 9
Cognitive Impairment in Parkinson’s Disease: What We Know so Far
Painous, C., & Martı́, M. J. (2020) · Research and Reviews in Parkinsonism · doi:10.2147/jprls.s263041 · Cited by 9
Insoluble α-synuclein in alzheimer’s disease without lewy body formation
Broe, M., Shepherd, C. E., Mann, D. M. A., Milward, E. A., Gai, W. P., Thiel, E., & Halliday, G. M. (2005) · Neurotoxicity Research · doi:10.1007/bf03033777 · Cited by 9
Dementia in Parkinson's disease
Martı́, M. J., TOLOSA, E. S., & de la Cerda, A. (2007) · Journal of Neurology · doi:10.1007/s00415-007-5007-5 · Cited by 9
Kahle, P. J., & Strooper, B. D. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor905 · Cited by 10
Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease
Trojanowski, J. Q. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64858-4 · Cited by 8
Johnson, J. O., Ostojic, J., Lannfelt, L., Glaser, A., Basun, H., Rogaeva, E. A., Kawarai, T., Bruni, A. C., George‐Hyslop, P. S., Goate, A., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.070 · Cited by 9
Bluhm, A., Schrempel, S., Schilling, S., von Hörsten, S., Schulze, A., Roßner, S., & Hartlage‐Rübsamen, M. (2022) · Biomolecules · doi:10.3390/biom12071006 · Cited by 8
Chen, L., Lu, H., Mao, L., Lin, J., & Liu, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39194 · Cited by 9
What we can learn from animal models about cerebral multi-morbidity
Baker, S. L., & Götz, J. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0097-2 · Cited by 8
Lin, C., Zheng, T.-L., Tsou, S., Chang, H., Tseng, L., Yu, C., Hung, C., & Ho, Y. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114035 · Cited by 8
Alpha-synuclein and Parkinson disease
LIU, H. (2007) · Neural Regeneration Research · doi:10.1016/s1673-5374(07)60053-x · Cited by 8
Chan, D. K. Y., Braidy, N., Xu, Y. H., Chataway, T., Guo, F., Guillemin, G. J., Teo, C., & Gai, W. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9644-2 · Cited by 8
Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein
Noronha, C., Perfeito, R., Laço, M., Wüllner, U., & Rego, A. C. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2199-7 · Cited by 8
α-Synuclein chaperone suppresses nucleation and amyloidogenesis of prion protein
Shirasaka, M., Kuwata, K., & Honda, R. P. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.120 · Cited by 8
da Silva, G. F. Z., & Ming, L. (2007) · Angewandte Chemie · doi:10.1002/ange.200604421 · Cited by 8
Kaur, G., Dewangan, J. P., Kumari, A. R., & Shukla, R. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2507637 · Cited by 7
Structural connectivity networks in Alzheimer’s disease and Lewy body disease
Baik, K., Yang, J., Jung, J. H., Lee, Y. H., Chung, S. J., Yoo, H. S., Sohn, Y. H., Lee, P. H., Lee, J., & Ye, B. S. (2021) · Brain and Behavior · doi:10.1002/brb3.2112 · Cited by 7
Sahoo, T. A., Chand, J., Kandy, A. T., Shanish Antony, A., & Subramanian, G. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04399-7 · Cited by 9
SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex
Brown, J. L., Hart, D. W., Boyle, G. E., Brown, T. G., LaCroix, M., Baraibar, A. M., Pelzel, R. J., Kim, M., Sherman, M. A., Boes, S. A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01480-y · Cited by 8
Mild cognitive impairment in dementia with Lewy bodies: an update and outlook
Jellinger, K. A. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02670-1 · Cited by 8
Emmer, K. L., Covy, J. P., & Giasson, B. I. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.12.005 · Cited by 7
Hartlage‐Rübsamen, M., Ratz, V., Zeitschel, U., Finzel, L., Machner, L., Köppen, J., Schulze, A., Demuth, H., von Hörsten, S., Höfling, C., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0726-2 · Cited by 7
Shin, E. J., & Park, J. W. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00058 · Cited by 7
Schützmann, M. P., & Hoyer, W. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169048 · Cited by 7
Hall, S. E., White, Z. J., Rohn, T. T., Sudasinghe, K., & Young, M. E. (2025) · Brain Sciences · doi:10.3390/brainsci15060631 · Cited by 6
Новиков, Н. Ю., Brazhnik, E. S., & Кичигина, В. Ф. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523110180 · Cited by 6
Aβ Puts the Alpha in Synuclein
Cook, C. N., & Petrucelli, L. (2020) · Neuron · doi:10.1016/j.neuron.2020.01.001 · Cited by 6
Natural IgG antibodies to β amyloid are decreased in patients with Parkinson’s disease
Paganelli, R., Paganelli, A., Pawelec, G., & Iorio, A. D. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00336-w · Cited by 6
Neuroimaging in Dementia: In Vivo Amyloid Imaging
Suhara, T., Higuchi, M., & Miyoshi, M. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.215.119 · Cited by 7
On the key role played by altered protein conformation in Parkinson’s disease
Agnati, L. F., Baldelli, E., Andreoli, N., Woods, A. S., Vellani, V., Marcellino, D. J., Guidolin, D., & Fuxé, K. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0072-1 · Cited by 6
Challenges and Opportunities Used in RNA-Based Therapeutics
Chauhan, P., Tiwari, I., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_10 · Cited by 5
Waqar, Z., Sethi, P., Jain, D., Singh, K., Alsaidan, O. A., Alzarea, S. I., Gupta, J. K., Saxena, S., & Sharma, M. C. (2025) · Current Genomics · doi:10.2174/0113892029372437251010114053 · Cited by 6
The Role of the Claustrum in Parkinson’s Disease and Vascular Parkinsonism: A Matter of Network?
Zedde, M., Quatrale, R., Cossu, G., Sette, M. D., & Pascarella, R. (2025) · Life · doi:10.3390/life15020180 · Cited by 6
Zhiyan, C., Min, Z., Yida, D., He, C., Hu, X., Yutong, L., Huan, W., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1424803 · Cited by 5
Zhang, X., Chen, Y., Tan, Y., Pan, T., & Wei, G. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037350729241129054701 · Cited by 6
Wu, C. (2011) · PubMed · Cited by 5
Investigating key factors underlying neurodegeneration linked to alpha‐synuclein spread
Pang, C. C.-C., Sørensen, M. H., Lee, K., Luk, K. C., Trojanowski, J. Q., Lee, V. M. ‐., Noble, W. J., & Chang, R. C. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12829 · Cited by 4
Pathobiological features in neurodegenerative diseases: an overview
Higuchi, M., Trojanowski, J. Q., & Lee, V. M. ‐. (2003) · International Congress Series · doi:10.1016/s0531-5131(03)01567-x · Cited by 5
The Pathogenesis of Alzheimer’s Disease: General Overview
Apostolova, L. G., & Cummings, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-36534-3_1 · Cited by 5
Ahammad, R. U., Spencer, B. J., Quach, B., Salehi, S. N., & Rissman, R. A. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70117 · Cited by 4
Amyloid Hypothesis and Alzheimer's Disease
Sun, X., & Zhang, Y. (2011) · InTech eBooks · doi:10.5772/28947 · Cited by 4
Varenyk, Y., Theodorakis, P. E., Pham, D. Q. H., Li, M. S., & Krupa, P. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c00503 · Cited by 4
Exploring α-Syn’s Functions Through Ablation Models: Physiological and Pathological Implications
Praveen, A., Dougnon, G., & Matsui, H. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01560-2 · Cited by 4
Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders
Allali, G., Kern, I., Laidet, M., Armand, S., & Assal, F. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171055 · Cited by 4
Booth, S., & Ko, J. H. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00842-9 · Cited by 4
Miyata, M., Kakeda, S., Yoneda, T., Ide, S., Okada, K., Adachi, H., & Korogi, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-21847-4 · Cited by 4
Lim, M. J., Boschen, S. L., Kurti, A., Casey, M. C., Phillips, V. R., Fryer, J. D., Dickson, D. W., Jansen‐West, K. R., Petrucelli, L., Delenclos, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102863 · Cited by 4
Metadata
- Authors
- Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-25
- Volume
- 98
- Issue
- 21
- Pages
- 12245-12250
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC59799
- OpenAlex
- W2131710583
- Cited by
- 607
- References
- 56
- Citations by year
- 2026: 8 · 2025: 26 · 2024: 17 · 2023: 23 · 2022: 17 · 2021: 17 · 2020: 39 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 26 · 2014: 44 · 2013: 29 · 2012: 24
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-05-22)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (AG5131, 5r29ag010869-05, AG‐18440, AG11385, AG10869)
- National Institute on Aging (AG-11385, R37AG018440, R37AG011385, R01AG018440, P50AG005131, AG-5131, AG 18440, AG10869, R01AG011385)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, alpha-synuclein, Alzheimer's disease, Parkinson's disease, Lewy body disease, transgenic mice, neuronal inclusions, alpha-synuclein aggregation, cholinergic neuron degeneration, motor impairment, learning and memory impairment, presynaptic terminals
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Cell Line, Disease Models, Animal, Female, Humans, Learning Disabilities, Male, Memory Disorders, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Parkinson Disease, Gene Expression, Amyloid beta-Peptides, Mice, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
